Biocharacteristics shared by highly protective vaccines against Marek's disease.
Attenuated serotype 1 Marek's disease virus strains vary widely in their protection properties. This study was conducted to elucidate which biocharacteristics of serotype 1 MDV strains are related with protection. Three pairs of vaccines, each one including a higher protective (HP) vaccine and a lower protective (LP) vaccine originating from the same MDV strain, were studied. Two other highly protective vaccines (RM1 and CVI988/BP5) were also included in the study. Comparison within pairs of vaccines showed that marked differences existed between the HP and the LP vaccines. Compared with LP vaccines, HP vaccines replicated better in vivo. Also, they induced a significant expansion of total T cells and of the helper and cytotoxic T cell lineages (CD45(+)CD3(+), CD4(+)CD8(-), CD4(-)CD8(+)) as well as a marked increase in the expression of the antigens of MhcI and MhcII on T cells. Thus, our results show that in vivo replication and early stimulation of the T-cell lineage are two characteristics shared by HP vaccines. However, comparison among the four HP vaccines that provided protection equal to that of CVI988 (RM1, CVI988/BP5, CVI988 and 648A80) revealed variability, especially regarding in vivo replication. Strains RM1 and CVI988/BP5 showed much stronger replication in vivo than the other two vaccine strains (CVI988 and 648A80). Thus, no single set of characteristics could be used to identify the most protective Marek's disease vaccines, implying, perhaps, that multiple mechanisms may be involved.
Gimeno
Isabel M
IM
USDA-ARS Avian Disease and Oncology Laboratory, East Lansing, MI, USA. igimeno@msu.edu
Witter
Richard L
RL
Hunt
Henry D
HD
Reddy
Sanjay M
SM
Reed
Willie M
WM
D000818:Animals; D002645:Chickens; D004279:DNA, Viral / Q000032:analysis; D005260:Female; D008381:Herpesvirus 2, Gallid / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity*; D008213:Lymphocyte Activation; D008297:Male; D008380:Marek Disease / Q000517:prevention & control*; D022501:Marek Disease Vaccines / Q000276:immunology* / Q000592:standards; D011201:Poultry Diseases / Q000276:immunology / Q000517:prevention & control*; D012703:Serotyping / Q000662:veterinary; D014613:Vaccines, Attenuated / Q000276:immunology / Q000592:standards; D014774:Virulence; D014776:Virus Cultivation; D014779:Virus Replication
D004279:DNA, Viral; D022501:Marek Disease Vaccines; D014613:Vaccines, Attenuated